aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

aTyr Pharma (NASDAQ:ATYR) announced its earnings results on Friday. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01, FiscalAI reports. The business had revenue of $189.56 million for the quarter.

aTyr Pharma Price Performance

Shares of ATYR stock traded up $0.01 during trading hours on Friday, hitting $0.51. The company had a trading volume of 355,761 shares, compared to its average volume of 1,115,501. The company’s fifty day moving average is $0.51 and its 200 day moving average is $0.70. aTyr Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $6.50. The stock has a market capitalization of $50.14 million, a PE ratio of -0.70 and a beta of 0.54.

Analysts Set New Price Targets

Several research firms have commented on ATYR. Weiss Ratings lowered aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Freedom Capital upgraded aTyr Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.00.

Insiders Place Their Bets

In other news, Director Paul Schimmel bought 100,000 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were bought at an average price of $0.50 per share, with a total value of $50,000.00. Following the completion of the transaction, the director directly owned 779,143 shares in the company, valued at $389,571.50. This trade represents a 14.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.75% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System purchased a new stake in shares of aTyr Pharma in the 2nd quarter valued at $28,000. Legal & General Group Plc purchased a new position in aTyr Pharma during the 2nd quarter valued at about $49,000. Prudential Financial Inc. acquired a new position in aTyr Pharma in the 2nd quarter valued at about $63,000. Oxford Asset Management LLP acquired a new position in aTyr Pharma in the 2nd quarter valued at about $70,000. Finally, Creative Planning purchased a new stake in aTyr Pharma during the second quarter worth about $74,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.